Opinion|Videos|November 22, 2024
T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights
Panelists discuss how the evolving treatment landscape for HER2-overexpressing NSCLC, particularly with the introduction of trastuzumab deruxtecan, influences therapeutic strategies and decision-making based on recent clinical trial data.
Advertisement
Episodes in this series
- (Rahul asks Rohit) Could you provide an overview of the current treatment landscape for HER2-overexpressing NSCLC? What is considered the SOC in various lines of treatment, and how do different therapeutic strategies—such as immunotherapy, chemotherapy, HER2-targeted therapies, and combination approaches—fit into various lines of treatment?
- (Rohit asks Levy, please state indication) T-DXd is approved for HER2-positive (IHC 3+) solid tumors after prior systemic therapy and is in the NCCN guidelines for IHC 3+ occult tumors.How has the emergence of HER2-targeted therapies, particularly trastuzumab deruxtecan, reshaped your treatment approach in HER2-overexpressing NSCLC from biomarker interpretation to treatment decision-making across different lines of therapy?
- With the advent of targeted therapies and personalized medicine, how has the interpretation of biomarker testing, including IHC scoring and disease drivers, shifted your treatment decision-making?
- (Rohit asks Rahul) Can you provide some background on clinical trial data updates with T-DXd in HER2-overexpressing NSCLC?
- DESTINY-Lung01: Cohort 1/1A (
Smit E. The Lancet. 2024 ) - DESTINY-Lung03 (
Planchard D. WCLC 2024. Abstract OA16.05 ) - (Rahul asks Levy) Given the data from these trials, how would you incorporate T-DXd into your treatment approach for patients with HER2-overpressing NSCLC?
- In which lines of therapy would you consider T-DXd in HER2-overexpressing NSCLC? (Please feel free to comment on your experience using T-DXd in HER2-mutant NSCLC)
Advertisement
Related to this article
An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
Lisa Carter-Bawa, PhD, APRN, discusses policy barriers, arts-based outreach, AI, and stigma in lung cancer screening.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.
Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.
Sofetabart mipitecan produced responses in heavily pretreated high-grade ovarian cancer regardless of folate receptor α expression or prior mirvetuximab soravtansine.
The European Commission approved the pembrolizumab-based regimen for resectable MIBC regardless of cisplatin eligibility based on the KEYNOTE-B15 data.
Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Expands Enfortumab Vedotin/Pembrolizumab Approval for Resectable MIBC
2
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
3
Sofetabart Mipitecan Shows Activity Across FRα Expression Levels in PROC
4
Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?
5